SCHEMBL30045100

SCHEMBL30045100

COc1cc(OC)c(Cl)c(-c2cc3cnc(SC)nc3c(N3CCCC3)n2)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TP53 P04637 1/20 0.35
▸ PDE4B Q07343 4/20 0.35
▸ PDE4A P27815 2/20 0.35
▸ PDE4C Q08493 2/20 0.35
▸ PDE4D Q08499 2/20 0.35
▸ PDE11A Q9HCR9 2/20 0.35
▸ PDE3B Q13370 1/20 0.35
▸ FGFR4 P22455 5/20 0.35
▸ FGFR1 P11362 3/20 0.35
▸ ADORA3 P0DMS8 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ CCNA2 P20248 1/20 0.33
▸ CDK2 P24941 1/20 0.33
▸ TTK P33981 1/20 0.33
▸ ACVR1 Q04771 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20331789 1.00 NOS1 (0.38) NOS1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL20331796 0.99 NOS1 (0.40) NOS1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21240537 0.98 NOS1 (0.36) NOS1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29578158 0.98 NOS1 (0.36) NOS1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL20331101 0.92 MEN1 (0.36) NOS1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29578278 0.91 PDE4B (0.45) NOS1KMT2AALDH1A1SMN1; SMN2PDE4B
SCHEMBL20331483 0.91 PDE4B (0.45) NOS1KMT2AALDH1A1SMN1; SMN2PDE4B
SCHEMBL20331794 0.89 PDE4B (0.35) NOS1MEN1KMT2ASMN1; SMN2TP53
SCHEMBL21240427 0.89 SUV39H2 (0.36) TP53PDE4BPDE4APDE4CPDE4D
SCHEMBL21240243 0.89 TTK (0.38) TP53PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-01-17 — — US disclosed
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2022-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FGFR4, FGFR2, FGFR1 NOS1 3282/4885MEN1 675/4885KMT2A 2963/4885
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 NOS1 3504/4885MEN1 745/4885KMT2A 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback